Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2025 11:45 ET | Source: Idorsia Pharmaceuticals Ltd

Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension

New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of...
November 10, 2025 09:52 ET | Source: Kestra Medical Technologies, Ltd.

Largest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device

KIRKLAND, Wash., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced primary results from...
November 10, 2025 08:00 ET | Source: Esperion Therapeutics, Inc.

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

– Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR...
November 10, 2025 08:00 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of...
November 10, 2025 07:30 ET | Source: Cytokinetics, Incorporated

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. ...
November 10, 2025 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy ...
November 10, 2025 07:00 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201...
November 09, 2025 16:15 ET | Source: Amarin Corporation plc

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a...
November 09, 2025 13:30 ET | Source: Heartflow, Inc.

AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification

NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the...
November 09, 2025 12:24 ET | Source: Intermountain Health

Intermountain Health Research: Targeted Vitamin D3 Supplementation Cuts Risk of Heart Attack Patients Having a Second Heart Attack in Half

NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- A tailored approach of vitamin D3 supplementation in patients who have suffered a heart attack significantly reduces their risk of a second heart...